K
Keith G. Mansfield
Researcher at Harvard University
Publications - 153
Citations - 10581
Keith G. Mansfield is an academic researcher from Harvard University. The author has contributed to research in topics: Simian immunodeficiency virus & Virus. The author has an hindex of 52, co-authored 148 publications receiving 9832 citations. Previous affiliations of Keith G. Mansfield include Centers for Disease Control and Prevention & Novartis.
Papers
More filters
Journal ArticleDOI
Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D
Peter Abbink,Angelique A. C. Lemckert,Bonnie A. Ewald,Diana M. Lynch,Matthew Denholtz,Shirley Smits,Lennart Holterman,Irma Damen,Ronald Vogels,Anna R. Thorner,Kara L. O'Brien,Angela Carville,Keith G. Mansfield,Jaap Goudsmit,Menzo J. E. Havenga,Dan H. Barouch +15 more
TL;DR: The construction of three novel rAd vector systems from Ad26, Ad48, and Ad50 are described and a detailed comparison of multiple rAd vectors from subgroups B and D is reported, which substantially expand the portfolio of rare serotype r adenovirus serotype vectors that may prove useful as vaccine vectors for the developing world.
Journal ArticleDOI
Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity
Diane M. Roberts,Anjali Nanda,Menzo J. E. Havenga,Peter Abbink,Diana M. Lynch,Bonnie A. Ewald,Jinyan Liu,Anna R. Thorner,Patricia E. Swanson,Darci A. Gorgone,Michelle A. Lifton,Angelique A. C. Lemckert,Lennart Holterman,Bing Chen,Athmanundh Dilraj,Angela Carville,Keith G. Mansfield,Jaap Goudsmit,Dan H. Barouch +18 more
TL;DR: Recombinant, replication-incompetent adenovirus serotype 5 (rAd5) vector-based vaccines for human immunodeficiency virus type 1 and other pathogens have proved highly immunogenic in preclinical studies but will probably be limited by the high prevalence of pre-existing anti-Ad5 immunity in human populations, particularly in the developing world.
Journal ArticleDOI
Immune Control of an SIV Challenge by a T Cell-Based Vaccine in Rhesus Monkeys
Jinyan Liu,Kara L. O'Brien,Diana M. Lynch,Nathaniel L. Simmons,Annalena La Porte,Ambryice M. Riggs,Peter Abbink,Rory Coffey,Lauren E. Grandpre,Michael S. Seaman,Gary Landucci,Donald N. Forthal,David C. Montefiori,Angela Carville,Keith G. Mansfield,Menzo J. E. Havenga,Maria G. Pau,Jaap Goudsmit,Dan H. Barouch +18 more
TL;DR: It is demonstrated that durable partial immune control of a pathogenic SIV challenge for more than 500 days can be achieved by a T-cell-based vaccine in Mamu-A*01-negative rhesus monkeys in the absence of a homologous Env antigen.
Journal ArticleDOI
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys
Dan H. Barouch,Dan H. Barouch,Jinyan Liu,Hualin Li,Lori F. Maxfield,Peter Abbink,Diana M. Lynch,M. Justin Iampietro,Adam J. SanMiguel,Michael S. Seaman,Guido Ferrari,Donald N. Forthal,Ilnour Ourmanov,Vanessa M. Hirsch,Angela Carville,Keith G. Mansfield,Donald Stablein,Maria G. Pau,Hanneke Schuitemaker,Jerald C. Sadoff,Erik Billings,Mangala Rao,Merlin L. Robb,Jerome H. Kim,Mary A. Marovich,Jaap Goudsmit,Nelson L. Michael +26 more
TL;DR: The proof-of-concept that optimized HIV-1 vaccine candidates can block acquisition of stringent, heterologous, neutralization-resistant virus challenges in rhesus monkeys is demonstrated.
Journal ArticleDOI
Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys
Dan H. Barouch,Dan H. Barouch,Kara L. O'Brien,Nathaniel L. Simmons,Sharon L. King,Peter Abbink,Lori F. Maxfield,Ying-Hua B. Sun,Annalena La Porte,Ambryice M. Riggs,Diana M. Lynch,Sarah L. Clark,Katherine Backus,James R. Perry,Michael S. Seaman,Angela Carville,Keith G. Mansfield,James J. Szinger,Will Fischer,Mark J. Muldoon,Mark J. Muldoon,Bette T. Korber,Bette T. Korber +22 more
TL;DR: It is shown that mosaic HIV-1 Gag, Pol and Env antigens expressed by recombinant, replication-incompetent adenovirus serotype 26 vectors markedly augmented both the breadth and depth without compromising the magnitude of antigen-specific T lymphocyte responses in rhesus monkeys.